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ABSTRACT
Introduction: Chronic low back pain (CLBP) is a
common condition and source of significant suffering,
disability and healthcare costs. Current physiotherapy
treatment is moderately effective. Combining theory-
based psychological methods with physiotherapy could
improve outcomes for people with CLBP. The primary
aim of this randomised controlled trial (RCT) is to
evaluate the efficacy of Physiotherapy informed by
Acceptance and Commitment Therapy (PACT) on
functioning in patients with CLBP.
Methods and analysis: The PACT trial is a two-
armed, parallel-group, multicentre RCT to assess the
efficacy of PACT in comparison with usual
physiotherapy care (UC). 240 patients referred to
physiotherapy with CLBP will be recruited from three
National Health Service (NHS) hospitals trusts.
Inclusion criteria are: age ≥18 years, CLBP ≥12-week
duration, scoring ≥3 points on the Roland-Morris
Disability Questionnaire (RMDQ) and adequate
understanding of spoken and written English to
participate. Patients will be randomised to PACT or UC
(120 per arm stratified by centre) by an independent
randomisation service and followed up at 3 and
12 months post randomisation. The sample size of 240
will provide adequate power to detect a standardised
mean difference of 0.40 in the primary outcome
(RMDQ; 5% significance, 80% power) assuming
attrition of 20%. Analysis will be by intention to treat
conducted by the trial statistician, blind to treatment
group, following a prespecified analysis plan.
Estimates of treatment effect at the follow-up
assessments will use an intention-to-treat
framework, implemented using a linear mixed-effects
model.
Ethics and dissemination: This trial has full ethical
approval (14/SC/0277). It will be disseminated via
peer-reviewed publications and conference
presentations. The results will enable clinicians,
patients and health service managers to make informed
decisions regarding the efficacy of PACT for patients
with CLBP.
Trial registration number: ISRCTN95392287;
Pre-results.
INTRODUCTION
Low back pain has a lifetime prevalence
ranging from 60% to 70% in industrialised
countries, causes more years of disability
than any other health condition and is the
second most frequent reason for absence
from work.1 2 Chronic low back pain (CLBP)
Strengths and limitations of this study
▪ The Physiotherapy informed by Acceptance and
Commitment Therapy (PACT) trial will be the first
randomised controlled trial to test the efficacy of
a physiotherapist-led ACT-informed intervention
for chronic low back pain (CLBP) against stand-
ard physiotherapy.
▪ The PACT trial will assess the feasibility of train-
ing physiotherapists to deliver a novel psycho-
logically informed physiotherapy intervention.
▪ Theory-based processes of change consistent
with the psychological flexibility model will be
evaluated, providing evidence for the mechani-
sms underpinning observed outcomes.
▪ Restriction to participants referred to physiother-
apy services and speaking English may limit gen-
eralisability of findings.
▪ Patients who have had prior treatment from
multidisciplinary or cognitive–behavioural
therapy (CBT) pain management at any time and
other physiotherapy treatment in the previous
6 months will be excluded due to possible con-
tamination effects.
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is pain that has lasted for more than 12 weeks. It causes
considerable suffering to the individual and is a major
ﬁnancial burden on the National Health Service (NHS)
and wider society. UK healthcare costs are £1.6 billion
annually,3 and CLBP is responsible for 80% of this cost.4
Physiotherapy is a common treatment for CLBP, with
1.26 million patients referred to NHS physiotherapists at
a cost of £150 million per annum.5 Several forms of
physiotherapy are recommended for CLBP, including
exercises, manual therapy and back classes.6 The type of
physiotherapy delivered varies considerably in duration
and content, and there is little consensus about the
most appropriate and cost-effective treatment.7 8 Many
trials show no clear superiority for any treatment, with
the majority leading to no more than modest improve-
ment in pain and disability outcomes.9 As a result,
patients are often overtreated, placing high demands on
physiotherapy services and delaying active self-
management. This highlights the need to develop and
test novel treatments for patients with CLBP.10
CLBP is best suited to a biopsychosocial model of
care11 and a cognitive behavioural approach to treat-
ment.12 Cognitive–behavioural therapy (CBT) has a
good evidence base for the treatment of chronic
pain.13–15 A Cochrane review concluded that further
general randomised controlled trials (RCTs) of CBT for
chronic pain were not required.16 Instead, studies identi-
fying the speciﬁc components of CBT and attempting to
understand which underlying processes were successful
were recommended. The Chartered Society of
Physiotherapy recognises that CBT can fall within a phy-
siotherapist’s scope of practice.17 However, CBT-based
treatments delivered by physiotherapists have only
produced moderate improvements in CLBP-related
disability,18 19 and many physiotherapists do not feel
adequately trained to use psychological techniques
effectively.20 There is potential for enhancing effective-
ness through greater focus on competency, but it
remains unclear how to best implement cognitive and
behavioural approaches during physiotherapy
interventions.
One promising theory-based approach to chronic pain
is a form of CBT called Acceptance and Commitment
Therapy (ACT).21 22 ACT has been shown to have posi-
tive effects in chronic pain,23 24 and meta-analyses of
ACT for chronic pain showed improvements in depres-
sion, anxiety, pain intensity, physical functioning and
quality of life (QoL).25 26 ACT aims to increase psycho-
logical ﬂexibility and focuses on improving function
rather than reducing pain. It has good maintenance of
treatment effects up to 3 years post treatment,27 import-
ant in a chronic relapsing and remitting condition such
as CLBP. In all published studies to date, ACT has been
delivered by psychologists or within multidisciplinary
teams; however, psychology is a limited resource and
most patients with CLBP are seen by physiotherapists.
A recent trial of ACT for CLBP delivered by psycholo-
gists found that patients referred for physiotherapy were
somewhat resistant to seeing a psychologist and conse-
quently has recommended combining ACT with physio-
therapy.28 A qualitative study investigated potential
barriers and facilitators to embedding ACT within a
physiotherapist-led pain rehabilitation programme.
Findings suggested this presented challenges and oppor-
tunities but was a positive experience overall if extra
support was provided.29
We have developed a brief physiotherapist-delivered
treatment, guided by principles of ACT, Physiotherapy
informed by Acceptance and Commitment Therapy
(PACT), consisting of two face-to-face sessions plus a
follow-up telephone call. A small proof-of-concept feasi-
bility study demonstrated the acceptability of the inter-
vention for patients, and recruitment to a larger trial
was achievable.30 This protocol describes a phase II efﬁ-
cacy RCT using a two-armed, parallel-group design to
assess the efﬁcacy of PACT for improving function at
3 months in individuals with CLBP, in comparison with
usual physiotherapy treatment. Across three NHS trusts
(including six hospital centres), 240 people with CLBP
will be individually randomised to PACT or usual physio-
therapy care (UC). We hypothesise that the group
receiving PACT will have improved self-reported func-
tioning at the primary end point of 3-month follow-up
compared with UC. The PACT trial is funded by the
National Institute for Health Research (NIHR) Research
for Patient Beneﬁt programme, reference number
PB-PG-1112-29055.
METHODS AND ANALYSIS
Main research question
What is the efﬁcacy of PACT for improving functioning
in patients with CLBP?
Research objectives
Primary objectives
1. The primary objective of this study is to evaluate the
efﬁcacy of PACT on the primary end point of func-
tioning at 3-month follow-up.
Secondary objectives
1. To assess whether PACT has a positive impact on sec-
ondary outcomes: QoL and function in various
domains, process variables such as acceptance and
committed action, mood, self-efﬁcacy and pain com-
pared with UC at 3-month and 12-month follow-up.
2. To investigate optimal ways of training physiothera-
pists to work in extended roles and develop a PACT
training package for use in a deﬁnitive multicentre
trial.
3. To pilot methods and instruments needed to estimate
cost-effectiveness in a future phase III trial from a
health service and societal perspective.
4. To assess the acceptability of the intervention and
training for patients and clinicians via nested qualita-
tive studies.
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5. To investigate hypothesised processes of clinical
improvement following PACT, including predictors
and moderators of outcome, and treatment ﬁdelity.
Design
A phase II, assessor-blind, multicentre, two-armed,
parallel-group RCT.
Method
A total of 240 patients with CLBP will be individually
randomised to PACT or UC.
Setting
Participants will be recruited from secondary care physio-
therapy clinics in two NHS Foundation Hospital trusts in
London (Guy’s and St Thomas’ and King’s College
Hospital) and one in the South East of England (Ashford
and St Peter’s), UK. Treatment will take place in the
physiotherapy clinics based at the participating hospitals.
Eligibility
Inclusion criteria: Adults (aged 18 years and over) with
non-speciﬁc CLBP (conﬁrmed by a clinical physiother-
apist) of >12 weeks duration, with or without associated
leg pain and reporting a score of 3 points or more on
the Roland-Morris Disability Questionnaire (RMDQ).
Patients need to be able and willing to provide informed
consent and attend treatment at hospital. Potential parti-
cipants require a good understanding of spoken and
written English to complete trial data collection and par-
ticipate in the PACT programme.
Exclusion criteria: Prior treatment from multidisciplin-
ary CBT pain management at any time and other
physiotherapy treatment in the previous 6 months or
injection therapy within 3 months. Speciﬁc medically
diagnosed lumbar spine pathology (eg, inﬂammatory
arthritis, fracture or cancer). Patients with deteriorating
neurological signs (stable neurological signs and pain of
apparently neuropathic origin are not exclusion criteria)
and those with previous experience of or awaiting spinal
surgery. Patients with current psychiatric illness (eg,
severe depression, personality disorder or post-traumatic
stress disorder) and/or current drug or alcohol misuse
likely to interfere with treatment.
Withdrawal criteria: Participants will be withdrawn from
the trial if there are any concerns regarding informed
consent. Participants can also withdraw if they choose to
without giving a reason. If patients withdraw consent for
research follow-up during the trial, reasons for dropout
will be recorded where possible.
Planned interventions
Physiotherapy informed by Acceptance and Commitment
Therapy
PACT is a brief physiotherapy intervention guided by
principles of ACT designed to promote self-management,
consisting of two 60 min face-to-face sessions 2 weeks
apart, plus one booster telephone call (lasting 20 min),
1 month after the last treatment session. PACT alters the
content of physiotherapy treatment and reconﬁgures it
so that it is delivered in fewer but longer sessions,
although the total contact time is similar to the average
amount of time patients with CLBP receive as part of
usual physiotherapy treatment as reported in two UK
RCTs for CLBP, where usual physiotherapy was used as
the control arm.31 32 Two 60-min sessions are designed
to allow adequate time to do an initial physical assess-
ment and provide feedback, create value-based goals,
provide individualised physical exercises and teach
simple psychological skills to promote psychological
ﬂexibility, and to address facilitators and barriers to self-
management. The booster phone call promotes self-
management by giving patients a chance to feedback
progress and gain support with any ongoing issues they
may have. PACT thus aims to directly reduce avoidance
and promote openness, to build present-focused aware-
ness, and coordinate greater engagement in goal-
oriented and value-based activity (see box 1 below). The
face-to-face intervention will be supported by a patient
manual individualised to patient needs. Patients rando-
mised to PACT will be given their patient manual during
their ﬁrst session.
Training and supervision
PACT will be delivered by 8 Band 6 or 7 trial phy-
siotherapists (2 per centre). Physiotherapists will be
identiﬁed by their managers and invited to volunteer to
take part in the study. The physiotherapist will then be
sent information about the PACT study and be invited to
meet the study team to discuss their participation.
Training will be provided by LM, a clinical psychologist
and expert in ACT, with the assistance of EG, a health
psychologist, and DC, a physiotherapist, before the start
of recruitment. Group face-to-face training including
experiential exercises and role play will last 2 days and
will be supported by a manual. The manual consists of
an introduction to ACT and promoting behaviour
change; information about the trial; strategies, meta-
phors and skills to enable PACT delivery; detailed
session plans (see box 1); explanation of competency
and ﬁdelity, including the use of supervision and a
reﬂexive diary. Obstacles to therapist and patient engage-
ment and progress will be discussed, as well as strategies
for dealing with these eventualities. The trial protocol
will be reviewed, including recording the timing and
length of sessions, any deviations from protocol includ-
ing missed sessions or dropout, and conﬁdential storage
of audio recordings. A training package will be further
developed through feedback forms ﬁlled in at the end
of the group face-to-face training and via interviews with
all trained physiotherapists as part of this study, to
enable its use in a larger phase III trial if PACT is suc-
cessful. Each physiotherapist will practise delivering
PACT and receive at least two sessions of individual
supervision to ensure adequate competency to com-
mence treatment. As PACT is a novel treatment, we will
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assess competency qualitatively through the training and
initial supervision process, which will include listening to
audiotaped sessions and observing role play.
Physiotherapists will also be asked to report back on
experiences with practice patients before they start the
trial. If a physiotherapist is not deemed competent to
begin delivery after two individual sessions of supervi-
sion, they will be offered more sessions until a satisfac-
tory level of competency is observed. We will continue to
assess competency throughout the trial on a monthly
basis. It is assumed competency will improve during the
course of delivery as skills are enhanced through prac-
tice and supervision. Trial physiotherapists will attend
monthly supervision meetings with supervisors (LM, EG
and DC), to maintain skills and receive support. Regular
supervision will ensure that the physiotherapists adhere
to the trial protocol and that the quality of the interven-
tion is maintained. Fidelity to the treatment protocol
will also be enhanced by the use of session checklists
and ratings of audio tapes from the trial with feedback
provided to clinicians.
Treatment fidelity
All PACT sessions will be audio-recorded for the purpose
of assessing treatment ﬁdelity. These will be used for
supervision during the study and to check ﬁdelity
throughout the trial. Supervisors will listen to one tape
per physiotherapist per month. Once the trial has
ended, a subset of the audio recordings will be analysed
for overall ﬁdelity. These ﬁdelity checks will be under-
taken via assessment of a sample of audio recordings of
PACT sessions, across sites and physiotherapists, under-
taken by two independent researchers. A modiﬁed ﬁdel-
ity measure will be developed based on the Plumb and
Vilardaga33 paper and the ACT for Chronic Pain
Adherence Rating Scale used in the Optimised
Behavioural Intervention trial.28 At least two sessions
from every physiotherapist will be rated in terms of
adherence to the manual and checklist. The therapeutic
alliance between physiotherapists and participants will
also be rated using a therapy process scale34 employed
in previous RCTs of treatments for chronic fatigue and a
weight loss intervention in primary care.
Usual care
Participants randomised to UC will receive any treat-
ment considered suitable by their treating physiother-
apist. Treatment may include any type of individual
physiotherapy and/or back classes, for example, exer-
cises, manual therapy, hydrotherapy and back schools.
Consistent with the Consolidated Standards of
Reporting Trials (CONSORT) guidelines for complex
interventions,35 we will collect data on volume (duration
and frequency of sessions) and components (eg,
one-to-one treatment vs group exercise class) of treat-
ment received by participants in the UC arm, and we
plan to report and publish these essential details of the
control condition with trial results.
Box 1 Summary of the content of Physiotherapy
informed by Acceptance and Commitment Therapy (PACT)
sessions
PACT Session 1: 60 min face to face
▸ Set the agenda: outline structure, schedule and delivery of
treatment.
▸ Assessment, feedback and rationale: conduct brief physical
assessment and discuss results. Empathise with and normal-
ise current feelings and provide guidance that no serious
medical problems have been uncovered and it is safe to
resume normal activities.
▸ Shifting focus from pain to function: discuss previous
attempts to reduce pain, which are not usually very successful
in relation to daily functioning. Build open engagement rather
than struggling with pain. Present the goal of PACT, to help
people function better, especially in the areas that are import-
ant to them. Use metaphors to help make this shift.
▸ Value-based goal setting: introduce patient manual. Engage
patient in identifying core values and setting related goals.
Break goals down into small steps that are positive, practical
and achievable, and record these in the manual.
▸ Skills training to address barriers to goal attainment: imple-
ment strategies to promote openness, awareness and engage-
ment, for example, mindfulness exercises, action plans and
making a public commitment to goals, to help anticipate and
overcome perceived barriers to change.
PACT Session 2: 60 min face to face
▸ Review successes and challenges: positively reinforce pro-
gress towards goals, discuss how this was achieved and high-
light benefits. Review, normalise and empathise with
challenges and encourage continued use of the patient
manual.
▸ Goal adjustment/development: check the salience of goals and
make adjustments if required. Re-establish commitment using
motivational interviewing techniques if necessary. Use exer-
cises and metaphors to normalise setbacks, keep moving in
small steps toward goals and troubleshoot or prevent the
effects of barriers.
▸ Generalisation to new areas: rehearse new skills, such as
mindfulness and shifting focus and explore how these can be
extended to other areas of life. Encourage the development of
insights and the capacity to self-initiate change.
▸ Integration of self-management approach: review key skills
and identify a support network. Discuss maintenance tools
and again normalise setbacks.
PACT Booster Call: 20-min phone call
▸ Review progress: appreciate successes to date and discuss
any remaining barriers.
▸ Assessment of skills integration into everyday life: review key
skill sets so that they organise the participant’s learning in the
areas of openness, awareness and engagement.
▸ Support generalisation: build on patterns of initial goal
achievement and broaden the scope of applications to other
areas.
▸ Reinforce continued self-management: emphasise to the
patient that they will face times in the future when they experi-
ence pain or other difficulties and they have resources to deal
with this, such as the patient manual and new skills. Positive
closure of the therapeutic partnership to help reinforce their
capacity to persist with the tools they have to manage their
back pain without needing more healthcare.
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Separate groups of clinicians will deliver PACT and UC
to avoid contamination. We will explicitly inform PACT
physiotherapists about the risks and consequences of
contamination during training and supervision and will
ask that they do not share material or ideas with their
colleagues during the treatment delivery period. In addi-
tion, we will ensure that all PACT sessions are conducted
in private rooms to eliminate the possibility of UC phy-
siotherapists overhearing what is being provided in the
novel treatment arm.
Participant identification and recruitment
In total, 240 patients will be recruited, 120 per treatment
arm, over an 18-month period. Patients will be recruited
from six secondary care physiotherapy clinics in London
and the South East of England. Posters advertising the
study will be placed in relevant physiotherapy clinics in
order to inform patients and clinicians about the study.
Potential participants referred to outpatient physiother-
apy by their general practitioner (GP) or consultant will
be identiﬁed by clinical physiotherapists from each hos-
pital centre at their initial triage sessions, provided with
written and verbal information about the PACT trial,
and invited to participate. Participants who consent to
be contacted will be referred to the research associates
(RAs) for full eligibility screening, conducted by tele-
phone. All patients who undergo screening will be
recorded anonymously on a screening database asso-
ciated with the study by the RAs. If the patient is suit-
able, the RA will then invite them to complete consent
forms and baseline measures either at home online, via
postal questionnaires or in person at the clinic (table 1).
GPs will be notiﬁed in writing of their patient’s partici-
pation. Patients will be informed that they can withdraw
from the study at any time without giving a reason and
that this will not affect the treatment they receive in any
way. All participant responses will be anonymous and
conﬁdential, and participants will not be identiﬁed in
any way by their responses (ﬁgure 1).
Study procedures
Information on study procedures is summarised in the
CONSORT diagram (ﬁgure 1) and table 1 (screening
and data collection).
Randomisation
Randomisation will be provided by an independent ran-
domisation service at the UK Clinical Research
Collaboration (UKCRC)-registered King’s Clinical Trials
Unit (CTU). Randomisation will be at the level of the
individual, using block randomisation with randomly
varying block sizes, stratiﬁed by centre and implemented
via the King’s CTU online system, with emails generated
automatically and sent to relevant physiotherapy staff at
study sites.
Blinding
It is not possible to blind patients or treating phy-
siotherapists to the treatment allocation; however, no
hypotheses have been proposed to participants as to
the superiority of PACT over UC and all participants
will receive physiotherapy treatment. The patient infor-
mation sheet will deliberately maintain a position of
equipoise by stating, ‘Each group will get a treatment
that we think might be helpful, but we don’t know
whether one treatment is going to be more helpful
than another’.
The RAs screening patients and collecting data and
the statistician analysing the data and assessing outcome
will be blinded to treatment allocation. All outcomes are
patient reported and collected via the internet following
automated email reminders, reducing the risk of
unblinding the assessors. Locked codes will be used for
treatment allocation, and the trial statistician will analyse
the data blind.
Data collection
Participant screening data will be collected by telephone
and entered into the database by the RAs. Baseline,
3-month and 12-month follow-up data will be collected
through self-report questionnaires. The RAs, blind to
treatment allocation, will administer questionnaires and
conduct data entry. Treatment allocation will not be
included on the questionnaires. Research data will be
entered onto the MedSciNet database system, a regula-
tory compliant database that has been enabled for
online collection of patient-reported outcome measures
(PROMS). Participants will be given a unique username
and password to log into the online database and com-
plete consent and measures at each time point. Their
data will be identiﬁed by a unique identiﬁcation number
and will be kept separate from any personal identifying
data to maintain conﬁdentiality. Baseline and outcome
data will be patient self-completed at home (either
online or via postal questionnaires), thus avoiding any
inﬂuence of the study team on the responses and redu-
cing bias. PACT physiotherapists will have access to a
unique database on the MedSciNet system to record
details of who provided PACT and UC sessions, the
number of sessions attended and any dropouts, as well
as the number and type of UC treatment sessions
attended.
Outcome measures
Time points: Assessments will be completed at baseline
(immediately pre-randomisation), and 3 months and
12 months post randomisation by all participants. All
time points will be taken into account during analysis,
but the primary efﬁcacy end point is 3-month follow-up.
In order to justify treatment costs, clinically signiﬁcant
treatment effects need to be maintained over time, and
this is particularly important in a chronic relapsing and
remitting condition such as CLBP, so maintenance of
any treatment effects will be assessed at 12 months. The
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RAs will be employed to coordinate the trial and collect
baseline and follow-up data. All participants will be sent
(emailed and posted) follow-up questionnaires by the
RAs at 3 and 12 months. Participants not returning ques-
tionnaires within 1 week will receive a reminder email,
telephone call and text in 3-day intervals. One week
after that, if no data have been returned, the RAs will
ring the participant to ask if they can collect primary
outcome data over the telephone.
Baseline measures
Participants will complete a baseline assessment question-
naire which includes the validated scales detailed below,
plus demographic data to establish sociodemographic
Table 1 Screening and data collection across the trial: summary of the key trial processes from a potential participant
agreeing to be contacted to the data collection time points
Process
Completed
by
Format of
administration Pre-consent Baseline
3-Month
follow-up
12-Month
follow-up
Ongoing
during
treatment
period Reference
Identification* PT PP ●
Screening RA Telephone ●
Consent P PP/DB ●
Randomisation CTU CTU Database ●
Sociodemographics P PP/DB ●
EuroQol-5D-5L P PP/DB ● ● ● 36
Medical Outcomes
Survey Short
Form-12 (V.2)
P PP/DB ● ● ● 37
Roland-Morris
Disability
Questionnaire
P PP/DB ● ● ● 38
Chronic Pain
Acceptance
Questionnaire-8
P PP/DB ● ● ● 39
Committed Action
Questionnaire-8
P PP/DB ● ● ● 40
Numeric Analogue
Scale
P PP/DB ● ● ● –
Patient-Specific
Function Scale
P PP/DB ● ● ● 41
Work and Social
Adjustment Scale
P PP/DB ● ● ● 42
Pain Self-Efficacy
Questionnaire
P PP/DB ● ● ● 43
Generalised Anxiety
Disorder-7
P PP/DB ● ● ● 45
Life Satisfaction
Scale
P PP/DB ● ● ● –
Patient Health
Questionnaire-9
P PP/DB ● ● ● 46
Global improvement P PP/DB ● ● 47
Satisfaction with
outcome
P PP/DB ● ● 47
Treatment credibility P PP/DB ● ● 48
Health-related
resource use
P PP/DB ● ● ● 49
Self-reported
adverse event
P PP/DB ● ● –
Clinician-reported
adverse event
PT PP/DB ● –
Treatment
attendance
PT DB ● –
*Includes permission to contact and provision of patient information letter.
CTU, King’s Clinical Trials Unit; DB, online database; P, participant; PP, paper and pencil; PT, physiotherapist; RA, research associate.
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characteristics of participants as follows: age, sex, height,
weight, self-reported ethnicity, education level, employ-
ment and beneﬁt status, diagnosis and history of any
medical condition if available.
Primary outcome: the RMDQ
Patient-reported disability is recommended as a core
outcome measure in low back pain14 and chronic pain
trials.50 The Roland-Morris Disability Questionnaire
(RMDQ)38 is a 24-item questionnaire assessing self-
reported functioning and disability due to CLBP,
ranging from 0 (no disability) to 24 (maximum disabil-
ity). The RMDQ is a widely used and valid measure with
good test–retest reliability. A 2–3 point change from
baseline is considered clinically important.51
Secondary outcome measures
Secondary outcomes have been selected to determine
the wider effects of PACT and to assess therapeutic pro-
cesses and mechanisms of action. The outcomes include
all core domains recommended in chronic pain
research:50 pain, function, mood, QoL and satisfaction
with treatment. A Global Improvement scale47 and
Treatment Credibility48 Questionnaire will be completed
at follow-up.
QoL: Work and Social Adjustment Scale (WSAS) and
EQ-5D-5L
The Work and Social Adjustment Scale (WSAS) measures
the effect of CLBP on participants’ ability to work and par-
ticipate in social and private leisure activities.42 The WSAS
has ﬁve items scored from 0 (not affected) to 8 (severely
affected), with a total possible score of 40. The EQ-5D-5L is
the most frequently used tool for generating quality-adjusted
life years (QALYs), which are favoured by the National
Institute for Health and Care Excellence (NICE).52
Pain: pain Numeric Analogue Scale (NAS)
A single pain item rated using a numerical analogue
scale anchored at 0 with ‘no pain’ and 10 with ‘worst
possible pain’ will reﬂect the participants’ subjective
experience of pain.
Function: Patient-Specific Functional Scale (PSFS)
The PSFS is a self-reported measure used to identify and
investigate functional status tailored to the patient.41
Figure 1 PACT trial process
flow chart. CTU, King’s Clinical
Trials Unit; PACT, Physiotherapy
informed by Acceptance and
Commitment Therapy. aGuy’s and
St Thomas’ Hospitals, King’s
College Hospital and Ashford and
St Peters Hospitals.
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The patient identiﬁes three activities limited by their
CLBP, rating them on a scale of 0 (unable to perform
activity) to 10 (able to perform activity at the same level
as before injury/problem). The scores across the three
items are summed to give a total possible score of 30.
Mood: Generalised Anxiety Disorder-7 (GAD-7) and Patient
Health Questionnaire-9 (PHQ-9)
The GAD-745 has seven items that assess anxiety in the
last 2 weeks. Scores range from 0 to 21, with a total score
of ≥8 indicating probable generalised anxiety disorder.
The PHQ-946 is a brief nine-item questionnaire that
identiﬁes and quantiﬁes depressive symptoms; scores
range from 0 to 27, with a total score of ≥10 indicating
probable depressive disorder. Both questionnaires are
well validated, commonly used self-report instruments
for detecting distress, depression and anxiety in patients
with medical illnesses.
Process variables
The Chronic Pain Acceptance Questionnaire-8 (CPAQ-8) and
Committed Action Questionnaire-8 (CAQ-8)
Acceptance of pain and persistent but ﬂexible behaviour
towards achieving a goal form part of the ACT model
and are therefore putative mediators of the efﬁcacy
mechanism in PACT treatment. The CPAQ-839 is a shor-
tened version of the original 20-item Chronic Pain
Acceptance Questionnaire, which assesses the capacity
to engage in activities without struggling with the pain.
Each item is scored from 0 (never true) to 6 (always
true), with a total possible score of 48. The CAQ-840 is a
shortened version composed of eight questions from the
original 18-item Committed Action Questionnaire aimed
to measure committed action in terms of commitment
to valued goals. The items are rated from 0 (never true)
to 6 (always true), with a total possible score of 48.
Pain Self-Efficacy Questionnaire (PSEQ)
The PSEQ43 assesses conﬁdence in undertaking normal
activities despite pain, which is an important variable to
measure in interventions designed to enhance self-
management. The questionnaire consists of 10 items
rated on a 7-point scale anchored at 0 with ‘not at all
conﬁdent’ and 6 with ‘completely conﬁdent’. Items are
summed to generate a total possible score of 60.
Satisfaction: satisfaction with life, global improvement,
treatment credibility
Satisfaction with treatment will be assessed by patients
rating their overall improvement in terms of Patient
Global Impression of Change (PGIC), their satisfaction
with outcome and how credible they found their treat-
ment.47 This has ﬁve items scored on 11-point scales
ranging from 0 (not at all) to 10 (completely). Life satis-
faction will be assessed by a single item: ‘All things con-
sidered, how satisﬁed are you with your life as a whole
nowadays?’ Responses are on a scale from 0 (extremely
dissatisﬁed) to 10 (extremely satisﬁed).
Health economics: EQ-5D-5L and SF-6D
This study is an important opportunity to pilot methods
for estimating the economic impact of interventions on
CLBP needed to design cost-effectiveness analyses
(CEAs) in future deﬁnitive trials. Previously reported
CEAs in the UK have relied on utility values derived
from two different instruments—the EQ-5D-5L36 52 53
and the SF-6D.18 The EQ-5D-5L is the most commonly
used tool for generating QALYs; however, the SF-6D,
which is derived from scores obtained on the Medical
Outcomes Survey Short Form-12 (v2), may be more sen-
sitive to change in CLBP. The economic burden of
CLBP is considerable from an NHS and patient perspec-
tive. A resource use questionnaire which identiﬁes key
cost drivers (NHS and non-NHS) will be developed
based on previous studies. This will then be piloted to
ensure completion rates, avoid redundant questions and
to identify any additional resource use items sensitive to
change in a CLBP population.54 This pilot study will
compare the validity and sensitivity of the EQ-5D-5L
(the most recent version of the EQ-5D) and the SF-6D
for use in economic evaluations of cognitively enhanced
physiotherapy for CLBP.
Adherence to PACT treatment
Patients’ adherence to PACT treatment will be recorded
by trial physiotherapists on a database. Attending both
face-to-face sessions will be considered adherence to
PACT treatment. In the UC arm, the type of treatment
and attendance at physiotherapy sessions will be
recorded by the trial physiotherapists on the database.
Any modiﬁcations or departures from randomised treat-
ments, withdrawal of participants from trial treatment or
research follow-up will be recorded and reported as
such.
Qualitative component
Patient interviews
A nested qualitative study will explore patients’ experi-
ences of PACT treatment. The aim of these methods will
be to assess patients’ views of the acceptability of PACT,
to provide insight into the quantitative results and to
explore processes of change. Semistructured face-to-face
interviews will be conducted with up to 25 participants
(sampled purposively to encompass a mix of gender,
age, recruitment site and baseline RMDQ scores) follow-
ing their 3-month follow-up assessment (RCT outcome
primary end point). Interviews will be transcribed verba-
tim and analysed using thematic analysis55 to generate
the key themes. Analysis will commence after the ﬁrst
interview in an iterative process, allowing early insights
to be explored more fully in later interviews and topic
guides to be amended as necessary. A reﬂexive diary will
be kept during the recruitment, interview and data ana-
lysis process to ensure transparency of the analysis
process. Respondent validity and independent coding by
another researcher will be conducted to check the validity
of emergent themes.
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Physiotherapist interviews
Additional, nested, longitudinal, qualitative methods will
explore the feasibility and acceptability of the PACT
training programme for physiotherapists. All phy-
siotherapists trained in PACT will be invited to attend
individual face-to-face semistructured interviews by inde-
pendent researchers. Later, the eight physiotherapists
providing PACT treatment will be interviewed on two
more occasions, 6 months after training and at the end
of treatment delivery, to assess their perceptions of deli-
vering this novel physiotherapy service treatment. All
qualitative interviews will provide insight into the accept-
ability and feasibility of PACT, development of compe-
tency and any contextual factors linked to delivery to
inform in any future research in this area.
Interviews will be conducted by independent research-
ers, transcribed verbatim and analysed using framework
analysis to generate the key themes.56 Analysis will com-
mence after the ﬁrst interview in an iterative process,
allowing early insights to be explored more fully in later
interviews and topic guides to be amended as necessary.
A reﬂexive diary will be kept during the recruitment,
interview and data analysis process to ensure transpar-
ency of the analysis process. Respondent validity and
independent coding by two researchers will be con-
ducted to check the validity of emergent themes.
Proposed sample size
The sample size of 240 will provide adequate power to
detect a standardised mean difference of 0.40 in the
primary outcome (RMDQ; 5% signiﬁcance, 80% power)
assuming attrition of 20%. Using data from Critchley
et al (2007) and our own initial feasibility study,57 30 this
equates to a 2-point difference between groups, where a
2–3 point difference in the RMDQ score is considered
clinically important.51 It is hoped attrition will be mini-
mised by a full explanation prior to recruitment of the
time commitment required and importance of complet-
ing all follow-up questionnaires. A protocol will be devel-
oped to ensure an optimum and standardised follow-up
process, including recording multiple contact addresses,
email addresses and phone numbers.
Statistical analysis
The statistical analysis plan has been approved by the
Trial Steering Committee (TSC). The trial will deter-
mine the efﬁcacy of the PACT intervention within six
secondary care physiotherapy clinics. The main efﬁcacy
analysis will be performed only once the database has
been cleaned and locked.
Stata 12.1 or higher will be used for the descriptive
and main inferential analyses. The main efﬁcacy analysis
for primary, secondary and process outcomes will follow
an intention-to-treat framework, whereby participants
are analysed according to the groups to which they were
randomised. The analysis will be conducted by the trial
statistician (SN) blind to group allocation. SN will only
be unblinded once the main efﬁcacy analysis has been
completed. Between-group differences (treatment efﬁ-
cacy) will be estimated for the primary outcome RMDQ
at the postintervention 3-month and 12-month follow-up
assessments using linear mixed-effects models. Random
effects for the intercept and time will be included in the
model. Treatment group, time and a treatment by time
interaction term will be included as covariates to allow
estimates of treatment effect at each time point to be
calculated. In addition, a random effect for physiother-
apist will be included to account for the partial cluster-
ing within physiotherapists in the intervention arm.
Estimation of the treatment effects on the secondary
and process outcomes will employ the same method as
the primary efﬁcacy analysis. All outcome variables are
continuous.
Planned secondary analysis will be performed to deter-
mine whether the treatment effect occurs via changes in
the process variables as hypothesised (pain acceptance
and committed action). Speciﬁcally, the proportion of
the treatment effect for disability (RMDQ), QoL (WSAS)
and mood (PHQ-9 and GAD-7) at each follow-up that is
mediated by the treatment effect on the process variables
at 3 months will be determined. This will be estimated by
the product of coefﬁcients method using bootstrapped
SEs.57 This analysis will be undertaken irrespective of
achieving the statistical signiﬁcance. Where the treat-
ment effect is non-signiﬁcant, additional further analysis
will be conducted to determine the role of post-
randomisation effect modiﬁers in the negative result
(adherence, treatment ﬁdelity and therapeutic alli-
ance). For example, should there be considerable non-
adherence to the treatment, the efﬁcacy of the treatment
for those who adhere to treatment will also be estimated
in terms of the complier average causal effect (CACE).
ETHICS AND DISSEMINATION
Ethical issues
The trial will be conducted in accordance with current
guidelines for ethical research conduct and subject to
full Research Ethics Committee (REC) approval
(National Research Ethics Committee South Central—
Berkshire; 14/SC/0277), including any provisions of
site-speciﬁc assessment, and local research and develop-
ment approval. It will comply with the International
Conference for Harmonisation of Good Clinical Practice
(ICH GCP) guidelines and the Research Governance
Framework for Health and Social Care. The trial is regis-
tered on a trial registry (ISRCTN95392287) and the lead
site (Guy’s & St Thomas’ NHS Foundation Trust; GSTT)
will audit this project annually to ensure compliance
with the necessary legislation.
All patients in the trial will beneﬁt from receiving
physiotherapy for their CLBP. This is a very low-risk study
as both treatments are non-invasive and delivered by
appropriately qualiﬁed physiotherapists. Patients attend-
ing PACT sessions should visit hospital less often and will
receive additional resources to aid self-management of
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their condition, possibly reducing its impact on partici-
pants’ lives. This may lead to beneﬁts for society and the
NHS, such as reduced healthcare usage and less time off
work, which is important in such a widespread and costly
condition. The disadvantage of taking part is the add-
itional time spent completing the questionnaires and for
some patients an interview. These should not take more
than 60 min in total to complete. Potential participants
will be fully informed of the trial procedures before
entering the study via a patient information sheet.
Informed consent
Potential participants will be identiﬁed by clinical phy-
siotherapists from each hospital centre, informed about
the RCT in writing and invited to participate. The
physiotherapist will explain that participation is com-
pletely voluntary and that they are free to refuse involve-
ment. They will be given at least 24 hours to consider
whether they would like to participate. The RAs will
then contact them to see if they are interested in partici-
pating and answer any questions about the study, prior
to conducting the screening process and signing the
consent form.
Fair access
Any adult patient referred to physiotherapy with low
back pain lasting over 12 weeks and good English will be
eligible for the trial. Participants will be able to com-
plete measures online, by post or in person, so they
should not be disadvantaged if they do not have access
to the internet.
Dissemination
The results of this study will be communicated to parti-
cipants at the end of the study and disseminated via
peer-reviewed publications, patient interest groups and
conference presentations. The results will enable clini-
cians, patients and health service managers to make
informed decisions regarding the efﬁcacy of PACT for
patients with CLBP. However, further studies will be
necessary to demonstrate the generalisability of the
ﬁndings beyond physiotherapy services in London
and the South East, as well its effectiveness and
cost-effectiveness.
Service user involvement
CLBP patients have been involved in the design of the
PACT trial and service users have contributed to
the development of the patient guide. Participants from
the feasibility study have also provided input and feed-
back on the proposals for this RCT. One of them is now
the patient and public involvement (PPI) representative
for this study, providing ongoing input (informal feed-
back and participating in TSC meetings) to ensure it
addresses issues relevant to users.
Research governance
This study will be conducted in accordance with the
ICH GCP guidelines and the Research Governance
Framework for Health and Social Care. King’s College
London is the sponsor of the RCT.
The TSC will meet every 6 months to oversee the trial
procedures and ensure good conduct of the study. The
TSC has an independent chair and two independent
members plus a PPI representative. The trial manage-
ment team (EG, DC, LM and the RAs) will hold
monthly meetings to ensure the smooth running of the
trial. The RAs will circulate a monthly newsletter to sta-
keholders to review progress relative to the project plan
and highlight any issues that need to be addressed.
Members of the team will consult each other immedi-
ately by email and/or phone about any issues that arise
between meetings.
Monitoring and auditing
The study will be monitored and audited in accordance
with King’s College London procedures. All trial-related
documents will be made available on request for moni-
toring and audit by King’s College London, trial NHS
partners, the REC and other licencing bodies.
Assessment of safety
All patients will be assessed and treated by an experi-
enced grade 6 or 7 physiotherapist.
Adverse events
Any adverse events will be recorded by the treating
physiotherapist in the clinical notes and reported to the
RA and chief investigator immediately via email. Patients
will also be offered the opportunity to report any
adverse events on the follow-up questionnaires. If a
patient becomes distressed during treatment, then the
PACT physiotherapists will be adequately trained to deal
with this or to identify a need for more input/support
and refer them for an appropriate assessment. There
will be clinical supervisors available at each research site
if needed, and experienced psychologists will supervise
physiotherapists delivering PACT on a monthly basis.
Serious adverse events
An adverse event is deﬁned as serious if it results in an
outcome which is life-changing/threatening, disabling
or incapacitating. Any serious adverse events that are
recorded will be immediately referred to the chief inves-
tigator, who will assess whether it is an adverse reaction
that is classed as serious, whether it could have been
caused by the intervention and whether it is unex-
pected. Any serious adverse reactions will be reported to
the TSC for monitoring and advice. They will advise
whether the participant should be withdrawn from
either their randomised treatment or from the trial.
Arrangements will be made by the trial team for further
assessment and management as agreed with the relevant
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authorities, GP and participant. A report of the outcome
will be provided to the TSC within 1 month.
Stopping rules
The trial may be stopped prematurely by the sponsor or
chief investigator on the basis of new safety information
or for other reasons given by the TSC, regulatory author-
ity or ethics committee concerned. The trial may be
halted on the advice of the TSC if recruitment rates are
substantially below expected levels with no possibility of
remedial action or if there are serious adverse reactions
attributable to the trial which mean it is unsafe to con-
tinue. If the study is terminated prematurely, active parti-
cipants will be informed and no further participant data
will be collected.
Data storage
Data will be collected and retained in accordance with
the Data Protection Act 1998. The Data Protection
Policy of King’s College London will be complied with.
The responses to questionnaires will be stored in an
anonymised form on a password-protected university
computer. The anonymised paper questionnaires will be
stored in a locked ﬁling cabinet at Guy’s Campus, King’s
College London. Study documents (paper and elec-
tronic) will be retained in a secure location during and
after the trial has ﬁnished. All source documents will be
retained for a period of 5 years following the end of the
study. The chief investigator will be the custodian of the
data and the data will only be used by the study team.
Conclusions
This paper describes the protocol for the PACT study.
The PACT study RCT will assess the feasibility and
acceptability of delivering a novel psychologically
informed physiotherapy intervention with staff and
patients. It is the ﬁrst trial to test the efﬁcacy of an
ACT-informed, physiotherapist-delivered intervention for
CLBP. It is noted that further studies will be necessary to
demonstrate the generalisability of the ﬁndings beyond
physiotherapy services in London and the South East, as
well its effectiveness and cost-effectiveness.
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